Analysis of Clinical Trials of New Drugs for Liver Diseases in China

References

• McBrideG. Hepatitis B virus-induced liver cancer in Asian Americans: a preventable disease. J Natl Cancer Inst. 2008;100(8):528–529. doi:10.1093/jnci/djn12018398090
   PubMedGoogle Scholar
• YanYP, SuHX, JiZH, ShaoZJ, PuZS. Epidemiology of hepatitis B virus infection in China: current status and challenges. J Clin Transl Hepatol. 2014;2(1):15–22. doi:10.14218/JCTH.2013.0003026356070
   PubMedGoogle Scholar
• ZhouY, WanY, YeZW, HeZ, LiuQ, ShiY. How hepatitis B virus causes cirrhosis and liver cancer. Med Hypotheses. 2017;108:52–53. doi:10.1016/j.mehy.2017.08.00529055401
   PubMed Web of Science ®Google Scholar
• GanemD, PrinceAM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–1129. doi:10.1056/NEJMra03108715014185
   PubMed Web of Science ®Google Scholar
• LinL, YanL, LiuY, YuanF, LiH, NiJ. Incidence and death in 29 cancer groups in 2017 and trend analysis from 1990 to 2017 from the Global Burden of Disease Study. J Hematol Oncol. 2019;12(1):96. doi:10.1186/s13045-019-0783-931511035
   PubMed Web of Science ®Google Scholar
• LinL, YanL, LiuY, QuC, NiJ, LiH. The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the Global Burden of Disease Study 2017. Liver Cancer. 2020;9(5):563–582. doi:10.1159/00050856833083281
   PubMed Web of Science ®Google Scholar
• PalumboE. New drugs for chronic hepatitis B: a review. Am J Ther. 2008;15(2):167–172. doi:10.1097/MJT.0b013e318155a19118356637
   PubMed Web of Science ®Google Scholar
• HadziyannisSJ, PapatheodoridisGV. Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). J Hepatol. 2003;39(Suppl 1):S172–176. doi:10.1016/S0168-8278(03)00334-914708699
   PubMed Web of Science ®Google Scholar
• FanningGC, ZoulimF, HouJ, BertolettiA. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844. doi:10.1038/s41573-019-0037-031455905
   PubMed Web of Science ®Google Scholar
• SasaiM, YamamotoM. Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors. Int Rev Immunol. 2013;32(2):116–133. doi:10.3109/08830185.2013.77439123570313
   PubMed Web of Science ®Google Scholar
• JanssenHLA, BrunettoMR, KimYJ, et al. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018;68(3):431–440. doi:10.1016/j.jhep.2017.10.02729104121
   PubMed Web of Science ®Google Scholar
• MannsMP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis. 2002;22(Suppl 1):7–13. doi:10.1055/s-2002-3569512447724
   PubMed Web of Science ®Google Scholar
• AraseY, TsubotaA, SuzukiY, et al. A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients. Intern Med. 2003;42(10):941–946. doi:10.2169/internalmedicine.42.94114606705
   PubMed Web of Science ®Google Scholar
• SarucM, OzdenN, TurkelN, et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci. 2003;92(7):1386–1395. doi:10.1002/jps.1040112820143
   PubMed Web of Science ®Google Scholar
• ClarkDN, HuJ. Unveiling the roles of HBV polymerase for new antiviral strategies. Future Virol. 2015;10(3):283–295. doi:10.2217/fvl.14.11325893003
   PubMed Web of Science ®Google Scholar
• LiuXJ, LiuC, ZhuLY, et al. Hepalatide ameliorated progression of nonalcoholic steatohepatitis in mice. Biomed Pharmacother. 2020;126:110053. doi:10.1016/j.biopha.2020.11005332200254
   PubMed Web of Science ®Google Scholar
• KiserJJ, FlexnerC. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53(1):427–449. doi:10.1146/annurev-pharmtox-011112-14025423140245
   PubMed Web of Science ®Google Scholar
• SpenglerU. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018;183:118–126. doi:10.1016/j.pharmthera.2017.10.00929024739
   PubMed Web of Science ®Google Scholar
• SorianoV, VispoE, de MendozaC, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14(9):1161–1170. doi:10.1517/14656566.2013.79554323621117
   PubMed Web of Science ®Google Scholar
• GittoS, GamalN, AndreoneP. NS5A inhibitors for the treatment of hepatitis C infection. J Viral Hepat. 2017;24(3):180–186. doi:10.1111/jvh.1265727925362
   PubMed Web of Science ®Google Scholar
• TaoX, WangN, WangJ, et al. Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor. Antimicrob Agents Chemother. 2019;63(12). doi:10.1128/AAC.01237-19.
   Web of Science ®Google Scholar
• LinL, ChenY, YanL, et al. Analysis of clinical trials of new drugs in China as of 2019. Drug Discov Today. 2020;25(12):2080–2088. doi:10.1016/j.drudis.2020.09.03033017690
   PubMed Web of Science ®Google Scholar
• A 4-drug combination (Viekira Pak) for hepatitis C. JAMA. 2015;313:1857–1858.25965236
   PubMed Web of Science ®Google Scholar
• OparA. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov. 2010;9(7):501–503. doi:10.1038/nrd321420592732
   PubMed Web of Science ®Google Scholar
• KowdleyKV, GordonSC, ReddyKR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–1888.24720702
   PubMed Web of Science ®Google Scholar
• HalfonP, SarrazinC. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver Int. 2012;32(Suppl 1):79–87. doi:10.1111/j.1478-3231.2011.02716.x
   Web of Science ®Google Scholar
• ZhangJ, LiW, YuanQ, et al. Transcriptome analyses of the anti-proliferative effects of 20(S)-ginsenoside Rh2 on HepG2 cells. Front Pharmacol. 2019;10:1331. doi:10.3389/fphar.2019.0133131780945
   PubMed Web of Science ®Google Scholar
• SongBK, KimKM, ChoiKD, ImWT. Production of the Rare Ginsenoside Rh2-MIX (20(S)-Rh2, 20(R)-Rh2, Rk2, and Rh3) by enzymatic conversion combined with acid treatment and evaluation of its anti-cancer activity. J Microbiol Biotechnol. 2017;27(7):1233–1241. doi:10.4014/jmb.1701.0107728478658
   PubMed Web of Science ®Google Scholar
• LiQ, HuaiL, ZhangC, et al. Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. Int J Hematol. 2013;97(5):617–623. doi:10.1007/s12185-013-1317-923550021
   PubMed Web of Science ®Google Scholar
• ZhuJ, LiZ, ZhangG, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720. doi:10.1371/journal.pone.002372021887305
   PubMed Web of Science ®Google Scholar
• HaoH, ZhangQ, ZhuH, et al. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice. Eur J Immunol. 2019;49(12):2235–2244. doi:10.1002/eji.20194822531465113
   PubMed Web of Science ®Google Scholar